Nitrogen multiple breath washout test for infants with cystic fibrosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10377432" target="_blank" >RIV/00216208:11130/18:10377432 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/18:10377432

Výsledek na webu

<a href="https://doi.org/10.1183/13993003.00015-2018" target="_blank" >https://doi.org/10.1183/13993003.00015-2018</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1183/13993003.00015-2018" target="_blank" >10.1183/13993003.00015-2018</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Nitrogen multiple breath washout test for infants with cystic fibrosis

Popis výsledku v původním jazyce

We report our data regarding safety, feasibility and repeatability of N2-MBW in cystic fibrosis infants. Between January 2015 and January 2017, we performed lung function testing in 35 infants aged 6.7-25.2 months (median 14.7) with classical form of cystic fibrosis. Testing was performed in patients without any signs of acute respiratory infection for at least 14 days. We conclude that N2-MBW is an attractive alternative to SF6 washout even in cystic fibrosis infants. It is safe and feasible. Moreover, in some aspects, it may outperform the SF6 method because of its lower cost and lower technical demands of the measurement. The suitability of this variant for longitudinal follow-up is also higher. On the other hand, it must be acknowledged, that SF6 washout offers more precise measurement with respect to a few physiological mechanisms interfering with the methodology of MBW. Further data (e.g. regarding the normative values) are needed before widespread use of N2-MBW may be recommended.

Název v anglickém jazyce

Nitrogen multiple breath washout test for infants with cystic fibrosis

Popis výsledku anglicky

We report our data regarding safety, feasibility and repeatability of N2-MBW in cystic fibrosis infants. Between January 2015 and January 2017, we performed lung function testing in 35 infants aged 6.7-25.2 months (median 14.7) with classical form of cystic fibrosis. Testing was performed in patients without any signs of acute respiratory infection for at least 14 days. We conclude that N2-MBW is an attractive alternative to SF6 washout even in cystic fibrosis infants. It is safe and feasible. Moreover, in some aspects, it may outperform the SF6 method because of its lower cost and lower technical demands of the measurement. The suitability of this variant for longitudinal follow-up is also higher. On the other hand, it must be acknowledged, that SF6 washout offers more precise measurement with respect to a few physiological mechanisms interfering with the methodology of MBW. Further data (e.g. regarding the normative values) are needed before widespread use of N2-MBW may be recommended.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30209 - Paediatrics

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Respiratory Journal

ISSN

0903-1936

e-ISSN

—

Svazek periodika

52

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

4

Strana od-do

—

Kód UT WoS článku

000440567600004

EID výsledku v databázi Scopus

2-s2.0-85051543250